Jump to navigation Jump to search
Note: Zimberelimab is approved in China, but does not appear to have a brand name at this time.
Mechanism of action
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-30: Approved for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).
Also known as
- Code names: AB122, GLS-010